@article{APS6703,
author = {Shu-min Yuan and Kai Gao and Dong-mei Wang and Xiong-zhi Quan and Jiang-ning Liu and Chun-mei Ma and Chuan Qin and Lian-feng Zhang},
title = {Evodiamine improves congnitive abilities in SAMP8 and APP swe /PS1 ΔE9 transgenic mouse models of Alzheimer's disease},
journal = {Acta Pharmacologica Sinica},
volume = {32},
number = {3},
year = {2016},
keywords = {},
abstract = {Aim: To investigate the effect of evodiamine (a quinolone alkaloid from the fruit of Evodia rutaecarpa) on the progression of Alzheimer's disease in SAMP8 and APPswe/PS1ΔE9 transgenic mouse models.
Methods: The mice at age of 5 months were randomized into the model group, two evodiamine (50 mg·kg−1·d−1 and 100 mg·kg−1·d−1) groups and an Aricept (2 mg·kg−1·d−1) group. The littermates of no-transgenic mice and senescence accelerated mouse/resistance 1 mice (SAMR1) were used as controls. After 4 weeks of treatment, learning abilities and memory were assessed using Morris water-maze test, and glucose uptake by the brain was detected using positron emission tomography/computed tomography (PET/CT). Expression levels of IL-1β, IL-6, and TNF-α in brain tissues were detected using ELISA. Expression of COX-2 protein was determined using Western blot.
Results: In Morris water-maze test, evodiamine (100 mg·kg−1·d−1) significantly alleviated the impairments of learning ability and memory. Evodiamine (100 mg·kg−1·d−1) also reversed the inhibition of glucose uptake due to development of Alzheimer's disease traits in mice. Furthermore, the dose of evodiamine significantly decreased the expression of IL-1β, IL-6, TNF-α, and COX-2 that were involved in the inflammation due to Alzheimer's disease.
Conclusion: The results indicate that evodiamine (100 mg·kg−1·d−1) improves cognitive abilities in the transgenic models of Alzheimer's disease.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/6703}
}